| Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Candel Therapeutics / NGM:CADL |
£1.40
|
£6.47
|
362.14%
|
£323,499.99
|
|
Jun '22
|
Lord Sugar
|
|
Acl / NMS:ACLX |
£17.47
|
£72.69
|
316.08%
|
£291,259.33
|
|
May '22
|
Lord Reay
|
|
Novo Nordisk As / NYQ:NVO |
£56.40
|
£140.80
|
149.67%
|
£174,767.27**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Tg Therapeutics / NCM:TGTX |
£15.05
|
£32.00
|
112.62%
|
£148,837.21
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Fortress Biotech / NCM:FBIO |
£1.92
|
£2.94
|
53.13%
|
£107,187.50
|
|
Jul '25
|
Lord Fink
|
|
Avacta Group / LSE:AVCT.L |
£51.50
|
£77.00
|
49.51%
|
£104,660.19
|
|
May '22
|
Lord Triesman
|
|
Blue / NMS:BLUE |
£3.39
|
£4.97
|
46.61%
|
£102,625.36
|
|
Apr '21
|
Baroness Deech
|
|
Novo Nordisk As / NYQ:NVO |
£36.35
|
£50.29
|
38.35%
|
£96,844.57
|
|
Mar '24
|
Lord Petitgas
|
|
Royalty Pharma / NMS:RPRX |
£30.08
|
£38.81
|
29.02%
|
£90,315.83
|
|
Dec '22
|
Lord Hintze
|
|
Atai Life Sciences / NGM:ATAI |
£3.48
|
£4.42
|
27.01%
|
£88,908.05
|
|
Nov '21
|
Lord Sherbourne of Didsbury
|
|
Novo Nordisk As / NYQ:NVO |
£56.71
|
£70.73
|
24.73%
|
£87,313.29**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Mustang Bio / NCM:MBIO |
£1.04
|
£1.22
|
17.31%
|
£82,115.39
|
|
Apr '22
|
Lord Hylton
|
|
Genus / LSE:GNS.L |
£2,678.00
|
£2,560.00
|
-4.41%
|
£66,915.61
|
|
Jun '16
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£47.80
|
£45.15
|
-5.54%
|
£66,119.25
|
|
Nov '24
|
Lord Moynihan of Chelsea
|
|
Sab Biotherapeutics / NCM:SABS |
£3.95
|
£3.59
|
-9.11%
|
£63,620.25
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£54.95
|
£45.15
|
-17.83%
|
£57,515.92
|
|
Mar '14
|
Lord Glendonbrook
|
|
Bb Biotech / EBS:BION.SW |
£33.36
|
£27.20
|
-18.47%
|
£57,074.34**
|
|
Aug '23
|
Lord Nash
|
|
Relay / NGM:RLAY |
£10.62
|
£7.79
|
-26.65%
|
£51,346.52
|
|
May '23
|
Lord Stevens of Ludgate
|
|
Avacta Group / LSE:AVCT.L |
£112.00
|
£77.00
|
-31.25%
|
£48,125.00
|
|
Apr '24
|
Lord Grabiner
|
|
Novo Nordisk As / NYQ:NVO |
£127.46
|
£64.73
|
-49.22%
|
£35,549.19**
|
|
Nov '23
|
Lord Mance
|
|
Novo Nordisk As / NYQ:NVO |
£101.69
|
£50.29
|
-50.55%
|
£34,617.96
|
|
Jan '21
|
Lord Spencer of Alresford
|
|
Immupharma / LSE:IMM.L |
£12.65
|
£6.20
|
-50.99%
|
£34,308.30
|
|
Apr '24
|
Lord Willoughby de Broke
|
|
Novo Nordisk As / NYQ:NVO |
£122.75
|
£50.29
|
-59.03%
|
£28,678.62
|
|
Apr '22
|
Lord Spencer of Alresford
|
|
Oxford Nanopore / LSE:ONT.L |
£320.00
|
£130.70
|
-59.16%
|
£28,590.62
|
|
May '24
|
Lord Londesborough
|
|
Novo Nordisk As / NYQ:NVO |
£134.66
|
£50.29
|
-62.65%
|
£26,142.14
|
|
Mar '24
|
Lord Petitgas
|
|
Moderna / NMS:MRNA |
£111.98
|
£29.63
|
-73.54%
|
£18,522.06
|
|
Sep '21
|
Lord Darzi of Denham
|
|
Oxford Nanopore / LSE:ONT.L |
£612.60
|
£130.70
|
-78.66%
|
£14,934.70
|
|
Oct '15
|
Lord Hayward
|
|
Sage / NGM:SAGE |
£46.11
|
£8.68
|
-81.18%
|
£13,177.19
|
|
May '11
|
Lord Glendonbrook
|
|
Mesoblast / NMS:MESO |
£101.20
|
£18.40
|
-81.82%
|
£12,727.27
|
|
May '20
|
Lord Wolfson of Aspley Guise
|
|
Adc Therapeutics / NYQ:ADCT |
£30.00
|
£4.18
|
-86.07%
|
£9,753.33
|
|
Apr '19
|
Lord Nash
|
|
Eq / NCM:EQ |
£8.20
|
£0.69
|
-91.59%
|
£5,890.24**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Avenue Therapeutics / NCM:ATXI |
£12.00
|
£0.65
|
-94.58%
|
£3,793.42
|
|
Mar '23
|
Baroness Shields
|
|
Benevolentai / AMS:BAI.AS |
£2.46
|
£0.09
|
-96.14%
|
£2,703.25**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Adaptimmune / NMS:ADAP |
£1.47
|
£0.05
|
-96.70%
|
£2,309.52
|
|
Dec '22
|
Lord Hintze
|
|
Affimed / NGM:AFMD |
£21.20
|
£0.18
|
-99.14%
|
£599.29
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.